Robert D. Fechtner
Research Subjects
Robert D. Fechtner has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Albert S. Khouri
Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA
3 shared publicationsTony Realini
West Virginia University Eye Institute
3 shared publicationsAlbert J. Getson
Merck Research Laboratories, Blue Bell, Pennsylvania, USA
1 shared publicationAlbert S Khouri
1 shared publication- Albert S. Khouri
Institute of Ophthalmology & Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey
1 shared publication Andrew J. Michael
1 shared publication
Latest Publications
- Open Access
- 1 July 2011
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 5, 945-53
Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
Peer reviewed article authored by (Fechtner RD, Harasymowycz P, Nixon DR, Vold SD, Zaman F, Williams JM, Hollander DA). Read article or submit your manuscript for publishing.
- 1 July 2011
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 5, 945-53
Open AccessTwelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
Peer reviewed article authored by (Fechtner RD, Harasymowycz P, Nixon DR, Vold SD, Zaman F, Williams JM, Hollander DA). Read article or submit your manuscript for publishing.
- 1 March 2007
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 18 (2) , 104-109
Evolving global risk assessment of ocular hypertension to glaucoma
To discuss current knowledge of global risk assessment in ocular hypertension. The ophthalmologist treating patients with ocular hypertension is frequently faced with the clinical dilemma of which patients to treat and how vigorous treatment should be. The goal of risk assessment for glaucoma is to identify patients at greatest risk for symptomatic vision loss. Risk factors can be identified by history such as age, race, and family history or can be clinically observed by examination such as elevated intraocular pressure, optic nerve head appearance, central corneal thickness, and visual field abnormalities. Risk assessment is a well accepted tool in other fields of medicine. Parallels can be drawn between the evolution of risk assessment for coronary artery disease and glaucoma. Validated risk calculators for ocular hypertension are currently available mostly derived from the Ocular Hypertension Treatment Study. The aim of assessing global risk for conversion from ocular hypertension to glaucoma is to identify patients who are most likely to benefit from early treatment. Calculation of risk should be accompanied by thorough analysis of risks, benefits, and alternatives for the individual patient.
- 1 March 2007
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 18 (2) , 104-109
Evolving global risk assessment of ocular hypertension to glaucoma
To discuss current knowledge of global risk assessment in ocular hypertension. The ophthalmologist treating patients with ocular hypertension is frequently faced with the clinical dilemma of which patients to treat and how vigorous treatment should be. The goal of risk assessment for glaucoma is to identify patients at greatest risk for symptomatic vision loss. Risk factors can be identified by history such as age, race, and family history or can be clinically observed by examination such as elevated intraocular pressure, optic nerve head appearance, central corneal thickness, and visual field abnormalities. Risk assessment is a well accepted tool in other fields of medicine. Parallels can be drawn between the evolution of risk assessment for coronary artery disease and glaucoma. Validated risk calculators for ocular hypertension are currently available mostly derived from the Ocular Hypertension Treatment Study. The aim of assessing global risk for conversion from ocular hypertension to glaucoma is to identify patients who are most likely to benefit from early treatment. Calculation of risk should be accompanied by thorough analysis of risks, benefits, and alternatives for the individual patient.
- 1 January 2007
- Published by Springer Nature in Drugs & Aging
- Vol. 24 (12) , 1007-1016
Use of Fixed-Dose Combination Drugs for the Treatment of Glaucoma
Glaucoma is a leading cause of irreversible visual loss. This potentially blinding disease is a progressive optic neuropathy associated with elevated intraocular pressure (IOP). Initial therapy for glaucoma typically consists of topical medications or laser treatment to lower IOP. Frequently, more than one medication is required to achieve adequate control of IOP. However, more medications means more bottles and greater complexity for the patient. There are several potential benefits of fixed combination medications compared with using the individual components separately. These include a reduction in the total number of drops and preservative instilled per day, cost savings, improved tolerability and compliance and avoiding the washout effect resulting from rapid-sequence instillation of multiple drops. Attempts to develop effective fixed combinations of glaucoma medications date back several decades. In recent years, fixed combinations of commonly paired drugs have been approved by various regulatory bodies in different countries and have gained wide acceptance. Current commercially available, fixed combination drugs include the topical β-adrenoceptor antagonist timolol 0.5% combined with a prostaglandin, a topical carbonic anhydrase inhibitor or an α-adrenoceptor agonist. Although there is no uniformity among registration trial designs, most published literature compares the efficacy of the fixed combination to the individual components and to concomitant use of both components. Various factors inherent to study design such as medication run-in, washout periods and peak and trough effects have to be taken into consideration when analysing the demonstrated efficacy of fixed combinations. Fixed combination treatments offer effective IOP control while reducing the washout effect and exposure to preservatives. They are also convenient. However, fixed combinations also remove the possibility of titrating the individual components both in terms of concentration and timing of administration. In addition, fixed combinations might not always provide the same efficacy as proper use of the individual components. The clinician must make individualised assessments when weighing the convenience of these medications against their limitations for specific patients.
- 1 January 2007
- Published by Springer Nature in Drugs & Aging
- Vol. 24 (12) , 1007-1016
Use of Fixed-Dose Combination Drugs for the Treatment of Glaucoma
Glaucoma is a leading cause of irreversible visual loss. This potentially blinding disease is a progressive optic neuropathy associated with elevated intraocular pressure (IOP). Initial therapy for glaucoma typically consists of topical medications or laser treatment to lower IOP. Frequently, more than one medication is required to achieve adequate control of IOP. However, more medications means more bottles and greater complexity for the patient. There are several potential benefits of fixed combination medications compared with using the individual components separately. These include a reduction in the total number of drops and preservative instilled per day, cost savings, improved tolerability and compliance and avoiding the washout effect resulting from rapid-sequence instillation of multiple drops. Attempts to develop effective fixed combinations of glaucoma medications date back several decades. In recent years, fixed combinations of commonly paired drugs have been approved by various regulatory bodies in different countries and have gained wide acceptance. Current commercially available, fixed combination drugs include the topical β-adrenoceptor antagonist timolol 0.5% combined with a prostaglandin, a topical carbonic anhydrase inhibitor or an α-adrenoceptor agonist. Although there is no uniformity among registration trial designs, most published literature compares the efficacy of the fixed combination to the individual components and to concomitant use of both components. Various factors inherent to study design such as medication run-in, washout periods and peak and trough effects have to be taken into consideration when analysing the demonstrated efficacy of fixed combinations. Fixed combination treatments offer effective IOP control while reducing the washout effect and exposure to preservatives. They are also convenient. However, fixed combinations also remove the possibility of titrating the individual components both in terms of concentration and timing of administration. In addition, fixed combinations might not always provide the same efficacy as proper use of the individual components. The clinician must make individualised assessments when weighing the convenience of these medications against their limitations for specific patients.
- Open Access
- 1 September 2006
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 124 (9) , 1257-1262
Short-term Treatment of Cocaine and/or Methamphetamine Abuse With Vigabatrin
Research from JAMA Ophthalmology — Short-term Treatment of Cocaine and/or Methamphetamine Abuse With Vigabatrin — Ocular Safety Pilot Results
- 1 September 2006
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 124 (9) , 1257-1262
Open AccessShort-term Treatment of Cocaine and/or Methamphetamine Abuse With Vigabatrin
Research from JAMA Ophthalmology — Short-term Treatment of Cocaine and/or Methamphetamine Abuse With Vigabatrin — Ocular Safety Pilot Results
- 1 April 2006
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 124 (4) , 544
Laser Suture Lysis Through Thick Blebs Using the Blumenthal Lens
Review from JAMA Ophthalmology — Laser Suture Lysis Through Thick Blebs Using the Blumenthal Lens
- 1 April 2006
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 124 (4) , 544
Laser Suture Lysis Through Thick Blebs Using the Blumenthal Lens
Review from JAMA Ophthalmology — Laser Suture Lysis Through Thick Blebs Using the Blumenthal Lens
- 1 April 2004
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 15 (2) , 132-135
Fixed combinations of topical glaucoma medications
Topical medical therapy remains the first line of treatment in the management of glaucoma. Utilization studies and clinical trials have demonstrated that many patients with glaucoma require multiple medications to achieve adequate control of intraocular pressure. Fixed combinations of commonly used drugs have been developed, tested, and in some (but not all) cases, approved for use in the United States and abroad. In this review the authors discuss the principles of fixed combination therapy and examine the existing fixed combinations. The first modern combination product was the dorzolamide–timolol fixed combination. It works better than either constituent and at least as well as concomitant therapy with both constituents. In comparison with newer agents, the dorzolamide–timolol fixed combination was equal in efficacy to latanoprost monotherapy, timolol and unoprostone concomitant therapy, and timolol and brimonidine concomitant therapy. Concomitant latanoprost and brimonidine demonstrated better efficacy than the dorzolamide–timolol fixed combination. The latanoprost–timolol fixed combination is available in many countries but not the United States. This combination has demonstrated modest additional efficacy over latanoprost monotherapy. The latanoprost–timolol fixed combination provided greater efficacy than concomitant timolol and brimonidine. Fixed combinations offer benefits of convenience, cost, and safety, but limit individualization of dosing. Understanding the advantages and disadvantages of prescribing fixed combinations facilitates success in using these products in clinical practice.
- 1 April 2004
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 15 (2) , 132-135
Fixed combinations of topical glaucoma medications
Topical medical therapy remains the first line of treatment in the management of glaucoma. Utilization studies and clinical trials have demonstrated that many patients with glaucoma require multiple medications to achieve adequate control of intraocular pressure. Fixed combinations of commonly used drugs have been developed, tested, and in some (but not all) cases, approved for use in the United States and abroad. In this review the authors discuss the principles of fixed combination therapy and examine the existing fixed combinations. The first modern combination product was the dorzolamide–timolol fixed combination. It works better than either constituent and at least as well as concomitant therapy with both constituents. In comparison with newer agents, the dorzolamide–timolol fixed combination was equal in efficacy to latanoprost monotherapy, timolol and unoprostone concomitant therapy, and timolol and brimonidine concomitant therapy. Concomitant latanoprost and brimonidine demonstrated better efficacy than the dorzolamide–timolol fixed combination. The latanoprost–timolol fixed combination is available in many countries but not the United States. This combination has demonstrated modest additional efficacy over latanoprost monotherapy. The latanoprost–timolol fixed combination provided greater efficacy than concomitant timolol and brimonidine. Fixed combinations offer benefits of convenience, cost, and safety, but limit individualization of dosing. Understanding the advantages and disadvantages of prescribing fixed combinations facilitates success in using these products in clinical practice.
- 16 December 2003
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 82 (1) , 42-48
Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials
: Purpose: To compare the efficacy of the fixed dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™). Methods: Two 3‐month, parallel group, randomized, observer‐masked and patient‐masked, multicentre, clinical trials were performed in patients with ocular hypertension or open‐angle glaucoma. Study 1 (n = 256) was conducted in the United States and Study 2 (n = 288) was conducted in Europe/Israel. Patients could be included whether or not they were currently taking ocular hypotensive therapy, and regardless of the effectiveness of any previous therapy. Patients were washed out from their usual ocular hypotensive medications and then those with a baseline intraocular pressure (IOP) ≥ 24 mmHg were randomized to either the dorzolamide/timolol combination eye drops twice daily or latanoprost eye drops once daily in both eyes. Efficacy was assessed by daytime diurnal IOP (the mean of measurements made at 0800, 1000, 1400 and 1600 h). Results: At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2. After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 mmHg for latanoprost in Study 2. The difference between treatments in mean IOP change at 3 months was − 0.04 mmHg [95% confidence interval (CI) − 0.85, 0.77] in Study 1, and − 0.57 mmHg (95% CI − 1.31, 0.16) in Study 2. The probability that the true difference lay between − 1.5 and 1.5 mmHg, the predefined bounds for equivalance, was > 0.950 in both studies. Both treatments were well tolerated over 3 months, although ocular stinging occurred more frequently with the dorzolamide/timolol combination. Conclusion: The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
- 16 December 2003
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 82 (1) , 42-48
Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials
: Purpose: To compare the efficacy of the fixed dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™). Methods: Two 3‐month, parallel group, randomized, observer‐masked and patient‐masked, multicentre, clinical trials were performed in patients with ocular hypertension or open‐angle glaucoma. Study 1 (n = 256) was conducted in the United States and Study 2 (n = 288) was conducted in Europe/Israel. Patients could be included whether or not they were currently taking ocular hypotensive therapy, and regardless of the effectiveness of any previous therapy. Patients were washed out from their usual ocular hypotensive medications and then those with a baseline intraocular pressure (IOP) ≥ 24 mmHg were randomized to either the dorzolamide/timolol combination eye drops twice daily or latanoprost eye drops once daily in both eyes. Efficacy was assessed by daytime diurnal IOP (the mean of measurements made at 0800, 1000, 1400 and 1600 h). Results: At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2. After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 mmHg for latanoprost in Study 2. The difference between treatments in mean IOP change at 3 months was − 0.04 mmHg [95% confidence interval (CI) − 0.85, 0.77] in Study 1, and − 0.57 mmHg (95% CI − 1.31, 0.16) in Study 2. The probability that the true difference lay between − 1.5 and 1.5 mmHg, the predefined bounds for equivalance, was > 0.950 in both studies. Both treatments were well tolerated over 3 months, although ocular stinging occurred more frequently with the dorzolamide/timolol combination. Conclusion: The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
- 1 July 1998
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 126 (1) , 37-41
Anterior uveitis associated with latanoprost
- 1 July 1998
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 126 (1) , 37-41
Anterior uveitis associated with latanoprost
- 1 June 1996
- Vol. 5 (3) , 152-5
Glaucoma: outcomeology (Part II)